Yakir Moshe

Venetoclax is safe and efficacious in relapsed/refractory AML

Chezi Ganzel, Ron Ram, Alexander Gural et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 36 citations

Medicine, Hematology, Oncology +13

Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice

Arie Apel, Yakir Moshe, Yishai Ofran et al. · American Journal of Hematology · 2021 · 32 citations

Medicine, Oncology, Pharmacology +15

Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis

Ofir Wolach, Avraham Frisch, Liat Shargian et al. · Annals of Hematology · 2022 · 26 citations

Medicine, Hematology, Oncology +6

Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience

Ron Ram, Christof Scheid, Odelia Amit et al. · Haematologica · 2019 · 21 citations · Full text

Medicine, Hematology, Oncology +16

Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis

Shai Shimony, Jonathan Canaani, Eitan Kugler et al. · Annals of Hematology · 2022 · 21 citations

Pharmacy, Oncology, Pharmacotherapy +12